按行业排序
2018
10/19/21

Castle Biosciences to Acquire Cernostics

阅读更多
8/22/21

Solar Power Booms in Georgia, Where It Isn’t Mandated

阅读更多
7/19/21

MINDERA™ ANNOUNCES PUBLICATION OF AN ECONOMIC EVALUATION OF PRECISION MEDICINE TESTING FOR THE TREATMENT OF PSORIASIS

阅读更多
6/17/21

PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A用于Bentracimab的商业化

阅读更多
5/12/21

ALSS Secures $7M Series B Funding To Commercialize Novel Vaccine Delivery System For Poultry Industry

阅读更多
5/11/21

Mindera Raises Over $12M Series A-2 Financing

阅读更多
4/30/21

BILLION-DOLLAR RANCH HANDS: How Silicon Ranch became a homegrown powerhouse

阅读更多
4/27/21

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

阅读更多
12/22/20

2021年最值得买入的21只股票

阅读更多
12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

阅读更多
12/15/20

Silicon Ranch Closes $225 Million Equity Raise with Existing Shareholders

阅读更多
11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

阅读更多
10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

阅读更多
10/6/20

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

阅读更多
9/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

阅读更多
7/27/20

Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer

阅读更多
6/24/20

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

阅读更多
5/27/20

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

阅读更多
1/13/20

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

阅读更多
1/10/20

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® forPB2452

阅读更多
11/21/19

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

阅读更多
11/19/19

Silicon Ranch signs on for 107-MW solar project for Facebook in Georgia

阅读更多
10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

阅读更多
10/15/19

PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

阅读更多
10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

阅读更多
8/14/19

PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

阅读更多
7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

阅读更多
6/26/19

Silicon Ranch Launches Regenerative Energy™

阅读更多
4/8/19

PhaseBio Announces Closing of Public Offering of Common Stock

阅读更多
4/8/19

PhaseBio Receives Breakthrough Therapy Designation

阅读更多
3/19/19

应用LifeSciences & Systems Announces Closing of its $8 Million Series A Round of Equity Financing

阅读更多
3/17/19

Full Results from PhaseBio Phase I Clinical Trial Published in New England Journal of Medicine

阅读更多
3/6/19

独立展望出版物, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

阅读更多
2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

阅读更多
1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

阅读更多
1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

阅读更多
12/6/18

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole加入董事会

阅读更多
12/5/18

Silicon Ranch to Help Power Facebook Data Center in Georgia

阅读更多
10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

阅读更多
8/27/18

PhaseBio Secures $34 Million in Series D Financing

阅读更多
7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

阅读更多
6/28/18

APPELLO完成10美元.5 MILLION SERIES A FINANCING LED BY DEERFIELD MANAGEMENT AND MOUNTAIN GROUP PARTNERS

阅读更多
3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

阅读更多
1/22/18

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

阅读更多
1/22/18

Shell Acquires Interest in Silicon Ranch Corporation

阅读更多
1/4/18

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc.该公司的A轮融资为1,000万美元

阅读更多